

UCLA Jonsson Comprehensive Cancer Center NEWSLETTER



Get Connected: Share Your Research on Facebook

Did you know that the JCCC Facebook page now reaches thousands of users worldwide every month? Newly relaunched with Timeline, the [UCLA Fights Cancer Facebook page](#) delivers the latest news about your research to our daily readership, along with all current JCCC and JCCF events and happenings. So [click over](#) and "Like" our page today to help us spread the word to your network of friends and colleagues.

Shared Resources at UCLA

- As a member you have access to 10 shared resources at JCCC, and over 70 additional shared resources at UCLA. Visit the [Shared Resources page](#) to learn more.

Meet Your Fellow Members

- JCCC is a scientific community over 400 members strong. In our ongoing [Researcher Profiles archive](#), read detailed biographies of many of your fellow members.

Funding Opportunities

- Members can now [access online](#) a complete list of the latest intramural and extramural grant opportunities directly from the JCCC website.

Latest Grant Awards

- All new funding awards are now being archived monthly on the JCCC website. [Click here](#) for a complete listing of the latest recipients and their awards.

Social Networking Tools

- JCCC is now on Twitter, Facebook and YouTube! Learn how to follow us and stay connected!



Latest News

Q2 Clinical Trials Pocket Guide Available Apr. 16



Published quarterly, the clinical trials pocket guide puts all currently open JCCC clinical trials right at your fingertips. Perfectly sized to fit inside a lab coat pocket and offering a complete list of open trials by anatomic site, it's free to JCCC members. Q2 guides will be available beginning April 16, and to reserve your copy, contact Emma Ashley at EAshley@mednet.ucla.edu.

Early PET Response Predicts Increased Survival in Sarcoma Patients



In a study led by JCCC scientist Dr. Fritz Eilber, UCLA researchers have discovered that soft tissue sarcoma patients with an early Positron Emission Tomography (PET) response after an initial round of chemotherapy can be used to predict increased survival rates, a finding that can improve patient care outcomes and overall effectiveness of drug treatments.

[Read More >](#)

Bid Now: Taste for a Cure Auction Opportunities



Don't miss the opportunity to support the JCCC's signature fundraising event, Taste for a Cure, on April 20th at the Beverly Wilshire Hotel. Tickets are still available, or you can show your support by bidding on our exceptional online auction packages now until April 20th. Each winning bid will help sustain the JCCC's vital research programs. For full event and auction details, visit www.tasteforacure.com.

Second Mutation in BRAF-mutated Melanoma not Contributing to Drug Resistance

In a finding that runs counter to what scientists expected to be true, a second mutation discovered in the tumors of patients with BRAF-mutated metastatic melanoma does not contribute to resistance to BRAF inhibitor drugs. The study, led by JCCC member Roger Lo, also found that patients with the mutations in both the MEK1 and BRAF genes respond



as well to the inhibitors as patients with the BRAF mutation alone.

[Read More >](#)

© 2011 UCLA Jonsson Comprehensive Cancer Center. All Rights Reserved.

[Terms & Conditions](#) | [Privacy Practices](#) | [About the JCCC Website](#)

Have feedback on this newsletter? Direct your questions and comments to: newsletter@mednet.ucla.edu